HUP0105070A2 - Novel treatment - Google Patents
Novel treatmentInfo
- Publication number
- HUP0105070A2 HUP0105070A2 HU0105070A HUP0105070A HUP0105070A2 HU P0105070 A2 HUP0105070 A2 HU P0105070A2 HU 0105070 A HU0105070 A HU 0105070A HU P0105070 A HUP0105070 A HU P0105070A HU P0105070 A2 HUP0105070 A2 HU P0105070A2
- Authority
- HU
- Hungary
- Prior art keywords
- hepatitis
- treatment
- prevention
- antiviral agent
- novel treatment
- Prior art date
Links
- 208000002672 hepatitis B Diseases 0.000 abstract 3
- 239000003443 antiviral agent Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 abstract 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A tal lm ny hepatitisz B vírusfertőzés megelőzésére és kezeléséreszolg ló gyógy szati készletre vonatkozik, mely hatóanyagként (1)valamely hepatitisz B elleni aktivit ssal rendelkező antivir lisszert, valamint (2) a hepatitisz B fertőzés megelőzésére és kezelésérealkalmas vakcin t tartalmaz. A hatóanyagokkal t"rténő kezelés szimultn, illetve szekvenci lisan végezhető. A tal lm ny szerinti készletantivir lis szerként előny"sen valamely nukleotid-analógot, hepatitiszB vakcinaként pedig hepatitisz B vírus felületi antigént tartalmaz. ÓThis applies to a medicinal kit for the prevention and treatment of hepatitis B virus infection, which contains as active ingredients (1) an antiviral agent with activity against hepatitis B, and (2) a vaccine suitable for the prevention and treatment of hepatitis B infection. The treatment with the active substances can be carried out simultaneously or sequentially. The kit according to the invention preferably contains a nucleotide analogue as an antiviral agent, and hepatitis B virus surface antigen as a hepatitis B vaccine. HE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9900630 | 1999-01-12 | ||
| PCT/EP1999/010295 WO2000041463A2 (en) | 1999-01-12 | 1999-12-21 | Combination of hepatitis b vaccine with antiviral agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0105070A2 true HUP0105070A2 (en) | 2002-04-29 |
Family
ID=10845878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0105070A HUP0105070A2 (en) | 1999-01-12 | 1999-12-21 | Novel treatment |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1140163A2 (en) |
| JP (1) | JP2002534438A (en) |
| KR (1) | KR20010090011A (en) |
| CN (1) | CN1391482A (en) |
| AR (1) | AR022250A1 (en) |
| AU (1) | AU760574B2 (en) |
| BR (1) | BR9916893A (en) |
| CA (1) | CA2359110A1 (en) |
| CO (1) | CO5241355A1 (en) |
| CZ (1) | CZ20012544A3 (en) |
| HK (1) | HK1041434A1 (en) |
| HU (1) | HUP0105070A2 (en) |
| IL (1) | IL144186A0 (en) |
| NO (1) | NO20013337L (en) |
| NZ (1) | NZ512890A (en) |
| PL (1) | PL349347A1 (en) |
| TR (1) | TR200102024T2 (en) |
| WO (1) | WO2000041463A2 (en) |
| ZA (1) | ZA200105690B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL139813A0 (en) | 1998-05-22 | 2002-02-10 | Loeb Health Res Inst At The Ot | Methods and products for inducing mucosal immunity |
| DK1103564T3 (en) | 1998-07-31 | 2009-05-11 | Int Inst Cancer Immunology Inc | Cancer antigens based on the tumor suppressor gene WT1 product |
| JP3728439B2 (en) | 2001-03-22 | 2005-12-21 | 治夫 杉山 | WT1 modified peptide |
| WO2003028757A1 (en) * | 2001-09-28 | 2003-04-10 | Haruo Sugiyama | Novel method of inducing antigen-specific t cells |
| US20050002951A1 (en) * | 2001-09-28 | 2005-01-06 | Haruo Sugiyama | Novel method of inducing antigen-specific t cells |
| TWI275392B (en) * | 2002-04-08 | 2007-03-11 | Bristol Myers Squibb Co | Low dose liquid entecavir formulations and use |
| NZ540098A (en) | 2002-10-29 | 2008-09-26 | Coley Pharmaceutical Group Ltd | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
| CA2502015A1 (en) | 2002-12-11 | 2004-06-24 | Coley Pharmaceutical Group, Inc. | 5' cpg nucleic acids and methods of use |
| CN100443117C (en) * | 2003-05-13 | 2008-12-17 | 深圳康泰生物制品股份有限公司 | Hepatitis B treating vaccine prepn and its prepn process and use |
| US8541167B2 (en) | 2004-06-03 | 2013-09-24 | Saint Louis University | Methods and compositions for vaccination |
| WO2008104133A1 (en) * | 2007-02-28 | 2008-09-04 | Centro De Ingeniería Genética Y Biotecnología | Combination therapy for the treatment of chronic hepatitis b |
| WO2020134682A1 (en) * | 2018-12-24 | 2020-07-02 | 南京远大赛威信生物医药有限公司 | Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof |
| WO2022215737A1 (en) * | 2021-04-07 | 2022-10-13 | デンカ株式会社 | Adjuvant activity enhancer and adjuvant composition |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69031556T2 (en) * | 1989-07-25 | 1998-05-14 | Smithkline Beecham Biolog | Antigens and processes for their production |
| HUP0101047A3 (en) * | 1998-03-09 | 2004-10-28 | Smithkline Beecham Biolog | Combined vaccine compositions |
-
1999
- 1999-12-21 CZ CZ20012544A patent/CZ20012544A3/en unknown
- 1999-12-21 IL IL14418699A patent/IL144186A0/en unknown
- 1999-12-21 BR BR9916893-6A patent/BR9916893A/en not_active IP Right Cessation
- 1999-12-21 EP EP99965531A patent/EP1140163A2/en not_active Withdrawn
- 1999-12-21 AU AU21009/00A patent/AU760574B2/en not_active Ceased
- 1999-12-21 TR TR2001/02024T patent/TR200102024T2/en unknown
- 1999-12-21 WO PCT/EP1999/010295 patent/WO2000041463A2/en not_active Application Discontinuation
- 1999-12-21 KR KR1020017008833A patent/KR20010090011A/en not_active Application Discontinuation
- 1999-12-21 PL PL99349347A patent/PL349347A1/en not_active Application Discontinuation
- 1999-12-21 HU HU0105070A patent/HUP0105070A2/en unknown
- 1999-12-21 CA CA002359110A patent/CA2359110A1/en not_active Abandoned
- 1999-12-21 JP JP2000593088A patent/JP2002534438A/en active Pending
- 1999-12-21 CN CN99816471A patent/CN1391482A/en active Pending
- 1999-12-21 NZ NZ512890A patent/NZ512890A/en unknown
-
2000
- 2000-01-11 AR ARP000100107A patent/AR022250A1/en not_active Application Discontinuation
- 2000-01-12 CO CO00001261A patent/CO5241355A1/en not_active Application Discontinuation
-
2001
- 2001-07-05 NO NO20013337A patent/NO20013337L/en not_active Application Discontinuation
- 2001-07-11 ZA ZA200105690A patent/ZA200105690B/en unknown
-
2002
- 2002-02-19 HK HK02101211.9A patent/HK1041434A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000041463A2 (en) | 2000-07-20 |
| CZ20012544A3 (en) | 2002-01-16 |
| TR200102024T2 (en) | 2001-12-21 |
| WO2000041463A3 (en) | 2000-11-09 |
| EP1140163A2 (en) | 2001-10-10 |
| KR20010090011A (en) | 2001-10-17 |
| JP2002534438A (en) | 2002-10-15 |
| CO5241355A1 (en) | 2003-01-31 |
| NO20013337L (en) | 2001-08-17 |
| BR9916893A (en) | 2001-11-20 |
| HK1041434A1 (en) | 2002-07-12 |
| PL349347A1 (en) | 2002-07-15 |
| AU2100900A (en) | 2000-08-01 |
| NZ512890A (en) | 2003-09-26 |
| AU760574B2 (en) | 2003-05-15 |
| AR022250A1 (en) | 2002-09-04 |
| CN1391482A (en) | 2003-01-15 |
| NO20013337D0 (en) | 2001-07-05 |
| CA2359110A1 (en) | 2000-07-20 |
| IL144186A0 (en) | 2002-05-23 |
| ZA200105690B (en) | 2002-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20104960B (en) | USE OF [D-MeALa]3-[EtVal]4-CYCLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID [D-MeAla]3-[EtVal]4-CYCLOSPORIN | |
| HUP0102441A2 (en) | Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals | |
| HUP0202502A2 (en) | Peptides that block viral infectivity and methods of use thereof | |
| HUP0105070A2 (en) | Novel treatment | |
| HUP0002224A1 (en) | Benzimidazole derivatives of antivirus activity | |
| TR200402565T4 (en) | Use of ß-L-2'-deoxy-nucleosides in the treatment of hepatitis delta virus infection | |
| HUP0103319A2 (en) | Compositions for the treatment of hiv and other viral infections and their use | |
| HUP0400719A2 (en) | Compounds and methods for treatment and diagnosis of chlamydial infection | |
| HUP0100100A2 (en) | Hepatitis c inhibitor peptide analogues, pharmaceutical compositions comprising thereof and their use | |
| RS20120201A3 (en) | Methods and compositions for hepatitis c virus treatment | |
| TR199802329T2 (en) | Use of IL-12 and IFNalpha in the treatment of infectious diseases. | |
| MY141594A (en) | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES | |
| ATE327246T1 (en) | HEPATITIS C TRIPEPTIDE INHIBITORS | |
| WO2001077091A3 (en) | Ns5b hcv polymerase inhibitors | |
| HUP0202570A1 (en) | Compositions and therapeutic methods involving isoflavones and analogues thereof | |
| ATE306938T1 (en) | USE OF CPG AS AN ADJUVANT FOR HIV VACCINE | |
| HUP0402259A2 (en) | Vaccines | |
| HUP0301349A2 (en) | Formulations for il-11 | |
| ATE486634T1 (en) | CASPASE 3, 8, 9 OR 10 INHIBITORS IN COMBINATION WITH MEK INHIBITORS FOR THE TREATMENT OF INFLUENZA | |
| ATE458496T1 (en) | HIV VACCINES AND METHODS OF APPLICATION | |
| ATE339211T1 (en) | L-FMAU FOR THE TREATMENT OF HEPATITIS DELTA VIRUS INFECTION | |
| DK1053012T3 (en) | Pharmaceutical compositions comprising PEG asparaginase for the treatment of HIV infections | |
| HUP0200162A2 (en) | Cloning and expression of haemophilus somnus transferrin-binding proteins | |
| RU2006118106A (en) | CHIMERIC Adenovirus VECTOR TYPE 5 / TYPE 35 | |
| WO2004006848A3 (en) | Combination therapies with ftc for the treatment of hepatitis b virus infection |